PD-1/PD-L1免疫治疗晚期尿路上皮癌的研究进展

Dawei Tian
{"title":"PD-1/PD-L1免疫治疗晚期尿路上皮癌的研究进展","authors":"Dawei Tian","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.01.016","DOIUrl":null,"url":null,"abstract":"Cisplatin-based chemotherapy is not effective in patients with advanced urothelial carcinoma. Recently, the application of immunological checkpoint inhibitors has brought new insight to resolve this problem. Since May 2016, five drugs, including Atezolizumab, Pembrolizumab, Nivolumab, Avelumab, and Durvalumab, targeting the PD-1/PD-L1 pathway have been approved by the FDA for the treatment of cisplatin-ineligible patients with advanced urothelial carcinoma, of which Pembrolizumab and Atezolizumab are the first-line drugs in the above treatments. The clinical efficacy and safety of these drugs are similar in different trials, but only Pembrolizumab is supported by a current level I evidence from a large randomized phase clinical trials. The results show that in the case of cisplatin ineligibility, Pembrolizumab is more effective than the traditional salvage chemotherapy in overall survival rate. Pembrolizuma is most effective in the treatment of cisplatin-ineligible patients with advanced urothelial carcinoma, while Pembrolizumab and Atezolizumab have similar efficacy in clinical applications of patients with cisplatin ineffective. \n \n \nKey words: \nAdvanced urothelial carcinoma; Immune checkpoint inhibitors; PD-1/PD-L1; Clinical trials","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":"42 1","pages":"88-93"},"PeriodicalIF":0.0000,"publicationDate":"2019-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Research progress in immunotherapy against PD-1/PD-L1 for advanced urothelial carcinoma\",\"authors\":\"Dawei Tian\",\"doi\":\"10.3760/CMA.J.ISSN.1673-4181.2019.01.016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cisplatin-based chemotherapy is not effective in patients with advanced urothelial carcinoma. Recently, the application of immunological checkpoint inhibitors has brought new insight to resolve this problem. Since May 2016, five drugs, including Atezolizumab, Pembrolizumab, Nivolumab, Avelumab, and Durvalumab, targeting the PD-1/PD-L1 pathway have been approved by the FDA for the treatment of cisplatin-ineligible patients with advanced urothelial carcinoma, of which Pembrolizumab and Atezolizumab are the first-line drugs in the above treatments. The clinical efficacy and safety of these drugs are similar in different trials, but only Pembrolizumab is supported by a current level I evidence from a large randomized phase clinical trials. The results show that in the case of cisplatin ineligibility, Pembrolizumab is more effective than the traditional salvage chemotherapy in overall survival rate. Pembrolizuma is most effective in the treatment of cisplatin-ineligible patients with advanced urothelial carcinoma, while Pembrolizumab and Atezolizumab have similar efficacy in clinical applications of patients with cisplatin ineffective. \\n \\n \\nKey words: \\nAdvanced urothelial carcinoma; Immune checkpoint inhibitors; PD-1/PD-L1; Clinical trials\",\"PeriodicalId\":61751,\"journal\":{\"name\":\"国际生物医学工程杂志\",\"volume\":\"42 1\",\"pages\":\"88-93\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际生物医学工程杂志\",\"FirstCategoryId\":\"1087\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.01.016\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际生物医学工程杂志","FirstCategoryId":"1087","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.01.016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

以顺铂为基础的化疗对晚期尿路上皮癌患者无效。近年来,免疫检查点抑制剂的应用为解决这一问题带来了新的见解。自2016年5月以来,美国食品药品监督管理局批准了五种针对PD-1/PD-L1途径的药物,包括阿替珠单抗、Pembrolizumab、Nivolumab、Avelumab和Durvalumab,用于治疗不符合顺铂条件的晚期尿路上皮癌患者,其中Pembrolizhumab和阿替珠珠单抗是上述治疗的一线药物。这些药物的临床疗效和安全性在不同的试验中是相似的,但只有Pembrolizumab得到了来自大型随机期临床试验的当前I级证据的支持。结果表明,在顺铂不合格的情况下,Pembrolizumab在总生存率方面比传统的挽救性化疗更有效。Pembrolizuma在治疗不符合顺铂条件的晚期尿路上皮癌患者中最有效,而Pembrolizamab和Atezolizumab在顺铂无效患者的临床应用中具有相似的疗效。关键词:晚期尿路上皮癌;免疫检查点抑制剂;PD-1/PD-L1;临床试验
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Research progress in immunotherapy against PD-1/PD-L1 for advanced urothelial carcinoma
Cisplatin-based chemotherapy is not effective in patients with advanced urothelial carcinoma. Recently, the application of immunological checkpoint inhibitors has brought new insight to resolve this problem. Since May 2016, five drugs, including Atezolizumab, Pembrolizumab, Nivolumab, Avelumab, and Durvalumab, targeting the PD-1/PD-L1 pathway have been approved by the FDA for the treatment of cisplatin-ineligible patients with advanced urothelial carcinoma, of which Pembrolizumab and Atezolizumab are the first-line drugs in the above treatments. The clinical efficacy and safety of these drugs are similar in different trials, but only Pembrolizumab is supported by a current level I evidence from a large randomized phase clinical trials. The results show that in the case of cisplatin ineligibility, Pembrolizumab is more effective than the traditional salvage chemotherapy in overall survival rate. Pembrolizuma is most effective in the treatment of cisplatin-ineligible patients with advanced urothelial carcinoma, while Pembrolizumab and Atezolizumab have similar efficacy in clinical applications of patients with cisplatin ineffective. Key words: Advanced urothelial carcinoma; Immune checkpoint inhibitors; PD-1/PD-L1; Clinical trials
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
1974
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信